Vladimir Putin confirmed that Russia is close to taking a big step in the fight against cancer. During his speech at a Moscow forum on future technologies, the Russian president stated that they are “very close to creating the so-called cancer vaccines and new generation immunomodulatory drugs“.
Currently, several countries and companies are working on developing vaccines against this disease. During 2023, the british government signed an agreement with the German company BioNTech to launch clinical trials.
“I hope they will soon be used effectively as individual therapy methods“Vladimir Putin wished in his statements. Although Putin’s testimony shows progress in Russian science in the fight against cancer, we still need to know vital details such as against what types of cancer vaccines would be directed, how would they be appliedetc.
Russia is not the only country that has bet on the development of vaccines against cancer. During 2023, the British government reached an agreement with the German pharmaceutical company BioNTech to launch clinical trials that provide “personalized cancer treatments“, with the aim of achieving the 10,000 patients by 2030.
For their part, companies Moderna and Merck & Co they developed a experimental vaccine against this disease. According to a study found in intermediate phasethe injection reduces half the chance of death from melanoma – the deadliest skin cancer – after three years of treatment.
According to World Health Organizationcurrently there are six vaccines authorized against the human papillomavirus (HPV), the cause of many types of cancer, including cervical cancer. There are also approved treatments for hepatitis Bwhich can cause Liver cancer.
The Argentine vaccine
A few weeks ago, the Sales Foundation and Conicet announced the first approved vaccine against skin cancer. The development was led by the researcher Joseph Mordohsenior member of Conicet, head of the Cancerology laboratory at the Leloir Foundation and Deputy Director of the Oncology program at the Faculty of Medical Sciences of the University of Buenos Aires (UBA).
This vaccine is unique in the world because it increases the number and variety of lymphocytes in our immune system, which are responsible for attacking tumor cells. “It is the first vaccine approved against cutaneous melanoma in the world,” Mordoh assured.
conicet.jpg
Conicet
The injection will be named Vaccinmel and it was already approved by regulatory authorities in 2021, for use under special conditions. Your application will require a detailed patient monitoring.
The vaccine is designed to treat cutaneous melanoma in its early stages (IIB, IIC and IIA). The complete treatment consists of 13 applications the patient to be given during the period of two years.
The product will be delivered to the pharmacies of health institutions that will be in charge of the preparation for its application in patients designated by the treating doctors and will be available in Argentina. between March and April 2024. Furthermore, there are already countries in the region that have shown interest in Argentine development.
Over the next few months, Mordoh will carry forward the training of professionals (doctors and pharmacy staff) in the characteristics, application of the injection, contraindications, and other details. “The importance of this project not only lies in the fact that the melanoma patients They will have an alternative to prevent the disease from progressing to more advanced stages; but also, It is one more example that this type of technologies can be developed in the region”, concluded the researcher.
Source: Ambito
